Juvenile Idiopathic Arthritis (JIA) is a bit of a "catch-all" term for chronic inflammatory arthritis in children under 16 that lasts for at least 6 weeks. Since you're prepping for the UKMLA AKT, it's really important to get the subtypes straight because they love to test the specific clinical features and complications (especially the eyes!).

Let's break down the subtypes first, as that's usually where the exam questions live.

1. Subtypes of JIA

The International League of Associations for Rheumatology (ILAR) classifies JIA into several distinct groups:

• Oligoarticular JIA (Most Common):
  • Affects ≤ 4 joints in the first 6 months.
  • Typically affects large joints (like the knee).
  • High risk of chronic asymptomatic uveitis (requires regular slit-lamp exams!).
  • Often ANA positive.
• Polyarticular JIA:
  • Affects ≥ 5 joints in the first 6 months.
  • Can be Rheumatoid Factor (RF) positive or negative. RF+ behaves more like adult RA.
• Systemic JIA (Still's Disease):
  • Characterized by quotidian fever (spikes once daily then returns to normal).
  • Salmon-pink evanescent rash that appears with the fever.
  • Hepatosplenomegaly, lymphadenopathy, and serositis.
• Enthesitis-Related Arthritis (ERA):
  • Inflammation at the sites where tendons/ligaments attach to bone (e.g., Achilles tendon).
  • Often associated with HLA-B27; think of it as the pediatric version of ankylosing spondylitis.
• Psoriatic JIA:
  • Arthritis + Psoriasis, or arthritis + specific features (dactylitis/nail pitting).

2. Diagnosis

Diagnosis is primarily clinical. There isn't one single "JIA test," but we use labs to help sub-classify and rule out other things:

• Inflammatory markers: ESR and CRP are often raised (especially in systemic JIA).
• ANA (Antinuclear Antibody): Not diagnostic for JIA itself, but a positive ANA is a major risk factor for uveitis.
• RF (Rheumatoid Factor): Usually negative in kids, but positive in a small subset of polyarticular JIA.
• Imaging: X-rays are often normal early on but can show joint space narrowing or erosions later. Ultrasound is great for detecting subclinical synovitis.

3. DMARD Therapy

The goal is "treat to target"—we want zero joint inflammation to prevent permanent damage and growth issues.

• First-line (Bridge): NSAIDs and intra-articular corticosteroid injections are often used for immediate symptom control.
• First-line DMARD: Methotrexate is the gold standard for most JIA subtypes.
  • Note: Remember to co-prescribe Folic Acid and monitor FBC/LFTs.
• Biologics (if DMARDs fail):
  • TNF-inhibitors (e.g., Etanercept, Adalimumab) are very effective.
  • For Systemic JIA, we often target Interleukins instead (e.g., Anakinra for IL-1 or Tocilizumab for IL-6).

I'll pull up some high-yield lessons and a flowchart to help you visualize the management pathway.

I've put together a flowchart for you that simplifies the classification and management steps. It's a great way to visualize how we move from the initial joint count to long-term DMARD therapy.

One high-yield tip for the AKT: Systemic JIA is often considered a separate entity because its pathophysiology is more "autoinflammatory" than "autoimmune." This is why it responds so well to IL-1 and IL-6 blockers (like Anakinra or Tocilizumab) rather than the standard TNF-blockers used in other types.

Also, never forget the eyes! Even if a child's joints are feeling great, if they are ANA positive, they need regular slit-lamp exams because JIA-associated uveitis is notoriously asymptomatic until it causes permanent vision loss.

Would you like to try a few practice questions on this to see how it's tested, or should we look at some more detailed flashcards for the drug side effects?